Stock TH THERATECHNOLOGIES INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Theratechnologies Inc.

Equities

TH

CA88338H7040

Market Closed - Toronto S.E.
Other stock markets
 03:59:59 2024-07-09 pm EDT 		5-day change 1st Jan Change
2.1 CAD +10.53% Intraday chart for Theratechnologies Inc. +10.53% -1.87%
May. 23 Theratechnologies Up Near 5% In US After Hours On Data Related To Its Lead Investigational Peptide Drug Conjugate Candidate MT
May. 23 Theratechnologies Brief: Says Sudocetaxel Zendusortide ASCO 2024 Presentation "Demonstrates Signs of Long-Term Efficacy and Manageable Safety Profile in Patients with Solid Tumors" MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Theratechnologies Inc. Announces Frank Holler as Chair of the Board of Directors
Update On Theratechnologies; Down More Than 5% On TSX As Q1 Net Loss Narrows, Awaits FDA Decision
Theratechnologies Up Near 6% In US Premarket As Q1 Net Loss Narrows, Accelerates Phase 1 Trial of Ovarian Cancer Drug
Theratechnologies Inc. Reports Earnings Results for the First Quarter Ended February 29, 2024
Theratechnologies Inc. Re-Affirms Earnings Guidance for the Fiscal Year 2024
Theratechnologies Inc. Preclinical Data Presentation At AACR 2024 Highlights Versatility and Flexibility of SORT1+ Technology? Oncology Platform
Theratechnologies Inc. Appoints Elina Tea to its Board of Directors and as Member of the Company's Audit Committee
Theratechnologies To Present Preclinical Data at AACR on Multiple PDCs Showcasing Potential of SORT1+Technology Platform
Theratechnologies Inc. Announces That It Will Phase Down Its Preclinical Oncology Research Activities
Theratechnologies to Phase Down Preclinical Oncology Research Program
Theratechnologies Inc. Appoints Jordan Zwick to Its Board of Directors and as Member of the Audit Committee
Theratechnologies Inc. Initiates Increased Dose Level in Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer
Theratechnologies Inc. Announces Board Changes
Theratechnologies Down 30% In US Premarket -- Receives Refusal To File Letter From FDA
Theratechnologies Inc. Receives Refusal to File Letter for Trogarzo Intramuscular Method of Administration sBLA from FDA
Theratechnologies Reports Record Quarterly Revenue of US$23.5 Million, Q4 Net Loss of $0.08 Per Share
Theratechnologies Inc. Reports Earnings Results for the Full Year Ended November 30, 2023
Theratechnologies Inc. Provides Earnings Guidance for the Year 2024
Theratechnologies Inc. Announces Publication in Frontiers in Immunology That Deepens Understanding of Sudocetaxel Zendusortide Molecular Mechanism of Action
Theratechnologies Completes Enrollment of First Six Patients in Updated Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. TH Stock
  4. News Theratechnologies Inc.
  5. Other languages